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Abstract Cardiomyocyte contraction is regulated by
phosphorylation of sarcomeric proteins. Throughout the
heart regional and transmural differences may exist in pro-
tein phosphorylation. In addition, phosphorylation of sar-
comeric proteins is altered in cardiac disease. Heterogeneity
in protein phosphorylation may be larger in hypertrophic
cardiomyopathy (HCM) and dilated cardiomyopathy
(DCM) as it may be caused by multiple mutations in genes
encoding different sarcomeric proteins. Moreover, HCM is
characterized byasymmetric remodellingofthe heart.In the
present study we assessed if local differences in sarcomeric
protein phosphorylation are more evident in primary HCM
or DCM than in non-failing donors. Thereto, phosphoryla-
tion of the two main target proteins of the beta-adrenergic
receptor pathway, troponin I (cTnI) and myosin binding
protein C (cMyBP-C) was analysed in different parts in the
free left ventricular wall of end–stage failing HCM and
DCM patients and donors obtained during transplant sur-
gery. Intra-patient variability in protein phosphorylation
within tissue samples of approximately 2 g wet weight was
comparable between donor, HCM and DCM samples and
could partly be attributed to the precision of the technique.
Thus, our data indicate that within the precision of the
measurements small, biopsy-sized cardiac tissue samples
are representative for the region of the free left ventricular
wall from which they were obtained.
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Introduction
Primary hypertrophic cardiomyopathy (HCM) is charac-
terized by asymmetrical hypertrophy of the left ventricle
and septum, without underlying cardiac or vascular
abnormalities (Richardson et al. 1996) The prevalence of
primary HCM is 0.2% in the general population and in
about 60% of the cases a mutation is identiﬁed in one of the
13 genes encoding the sarcomeric proteins (Ramaraj 2008;
Richard et al. 2003, 2009). The clinical presentation and
development of HCM is very diverse, ranging from no
symptoms at all to end–stage heart failure. Primary dilated
cardiomyopathy (DCM) is characterized by eccentric
remodelling of the heart (Richardson et al. 1996). Although
20–48% of DCM cases are familial, only a small number of
mutations are known to date (Chang and Potter 2005). The
asymmetric remodelling observed in HCM and the variable
geno- and phenotypes in familial HCM and DCM raise the
question how representative small cardiac tissue sample are
for the region of the left ventricle (LV) they are taken from.
A characteristic feature of end-stage heart failure is
down regulation and desensitization of the b-adrenergic
receptor pathway, as a consequence of chronic stimulation
of the sympathetic system (Bristow et al. 1993; Hamdani
et al. 2008). Consequently, the downstream sarcomeric
target proteins cardiac troponin I (cTnI) and myosin
binding protein C (cMyBP-C) may become less phos-
phorylated by protein kinase A (PKA) (Bodor et al. 1997;
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Dijk et al. 2008). Therefore, we compared the variability in
phosphorylation of the b-adrenergic target proteins cTnI
and cMyBP-C within the left ventricle from HCM and
DCM tissue samples to cardiac tissue from donors.
Methods
Cardiac tissue
Tissue from the free LV wall from end-stage heart failure
patients clinically characterized with familial hypertrophic
(n = 5) or dilated (n = 5) cardiomyopathy was obtained
during cardiac transplantation surgery. Control cardiac LV
tissue was obtained from donor hearts (n = 5) for which no
suitable transplant recipient was found. The donors had no
history of cardiac disease, a normal ECG and normal
ventricular function on echocardiography performed within
24 h prior to heart explantation.
The tissue was collected in cold cardioplegic solution,
divided into pieces of approximately 2 g wet weight and
immediately frozen in liquid nitrogen. Samples were
obtained after informed consent and with approval of the
local ethical committee (St. Vincent’s Hospital Human
research Ethics Committee: File number H03/118; Title:
Molecular Analysis of Human heart Failure).
Protein phosphorylation
From each patient, four or ﬁve small pieces of about
0.5–1 mg wet weight were taken randomly from one LV
tissue sample. All samples were treated with trichloro
acetic acid prior to protein analysis to preserve the
endogenous phosphorylation status of the sarcomeric pro-
teins. Proteins in cardiac tissue homogenates were sepa-
rated on 4–15% Tris-HCl gels (Biorad) (Fig. 1). Each
sample was run in duplo on the gels. To detect protein
phosphorylation, the gels were stained with ProQ Dia-
mond. Subsequently the gels were stained with SYPRO
Ruby to determine protein content. Staining of the gels
was visualized using the Las-3000 Image Reader (Fuji;
460/605 nm) and analyzed with AIDA, as described before
(Zaremba et al. 2007). cMyBP-C phosphorylation level
was expressed relative to cMyBP-C content and cTnI
phosphorylation to a-actinin content to correct for loading
differences.
Data analysis
Data are presented as mean ± standard error of the mean
(SEM). The variance within each sample was expressed as
the coefﬁcient of variation. A comparison was made
between the mean coefﬁcient of variation in HCM, DCM
and donor with one-way ANOVA. P\0.05 was consid-
ered signiﬁcant.
Results
Inter- and intra-patient variability can partly be attributable
to imprecision of the technique used to determine protein
phosphorylation. The precision of the technique was esti-
mated by analyzing the difference between duplicate
measurements. The coefﬁcient of variation of the duplicate
measurements of cMyBP-C phosphorylation was higher in
HCM and DCM samples compared to donor (38 ± 10 and
39 ± 9 vs. 11 ± 2%, respectively). Lower variability was
seen in cTnI phosphorylation, though again the coefﬁcient
of variation was higher in HCM and DCM than in donor
(17 ± 3 and 24 ± 6v s1 0± 2%, respectively). The vari-
abilities between duplicate measurements are inversely
related with the absolute phosphorylation levels (i.e. higher
variability on low phosphorylation levels), indicating that
differences in variability are largely accountable to noise in
the measurement.
The variability within each LV sample was assessed by
determining how much each of the 4–5 randomly selected
tissue samples differed from the average of that heart and
expressed as the coefﬁcient of variation. The phosphoryla-
tion of cMyBP-C and cTnI in the different tissue samples
within the three groups is shown in Fig. 2, with the coefﬁ-
cientofvariationdepictedabovethebarsforeachindividual.
The coefﬁcient of variation of cMyBP-C phosphorylation
ranged from 6 to 20% in donor, from 9 to 138% in HCM and
from0to43%inDCMsamples(Fig. 2a,b,c).Similarly,the
variability in cTnI phosphorylation ranged from 15 to 35%
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Fig. 1 A representative gradient gel stained with ProQ Diamond and
SYPRO Ruby, demonstrating the phosphorylation status of cMyBP-C
and cTnI. MWM indicates molecular weight marker
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123among donor, from 9 to 22% between HCM and from 19 to
45% in DCM samples (Fig. 2d, e, f).
The variability within LV samples from each group was
compared using one-way ANOVA (Fig. 3). The average
coefﬁcient of variation of cMyBP-C phosphorylation was
slightly higher in HCM (46 ± 23%) and DCM (21 ± 6%)
compared to donor (11 ± 3%), but the difference was not
signiﬁcant (Fig. 3a, closed symbols). The relatively wide
spread in variability of cMyBP-C phosphorylation in HCM
andDCMcanbeexplainedbythezerophosphorylationlevel
in some of the samples from HCM 1 and DCM 3. The
cMyBP-Cphosphorylationinthesesampleswaspresumably
below the detection level of the ProQ Diamond stain.
Exclusion of HCM 1 and DCM 3 lowered the average
coefﬁcient of variation of cMyBP-C phosphorylation in
HCM to 23 ± 6%, while the mean coefﬁcient of variation
became slightly higher in DCM (25 ± 5%). Furthermore,
the large SEM of the coefﬁcient of variation in HCM was
lowered. Even after exclusion of HCM 1 and DCM 3 the
difference in average variance between HCM and DCM and
donor remained not signiﬁcant (Fig. 3a, open symbols).
Accordingly,itcanbeconcludedthattheaveragecoefﬁcient
of variation for cTnI phosphorylation (Fig. 3b; closed sym-
bols) did not differ signiﬁcantly among groups (14 ± 3% in
HCM; 28 ± 4% in DCM and 24 ± 4% in donor).
The average phosphorylation of cMyBP-C was lower in
HCM and DCM than in donor (HCM 0.2 ± 0.05, DCM
0.1 ± 0.03 and donor 0.4 ± 0.01). Post hoc analysis
indicated that cMyBP-C phosphorylation was signiﬁcantly
lower in DCM compared to donor. The average cTnI
phosphorylation was signiﬁcantly lower in both HCM and
DCM compared to donor (0.4 ± 0.01 and 0.6 ± 0.4 vs.
1.5 ± 0.1, respectively).
Discussion
In this study the variability in phosphorylation of
b-adrenergic target proteins within patients with HCM and
DCM was determined. A comparison was made between
protein phosphorylation status of cMyBP-C and cTnI in
HCM and DCM patients and in donor.
Although some variation was found between different
pieces from one heart sample, this variation was not sig-
niﬁcantly different in HCM and DCM samples compared to
donor samples. Furthermore, the coefﬁcient of variation of
the cMyBP-C and cTnI phosphorylation in hearts was in
the same range as the variability of the duplicate mea-
surements on the ProQ stained gels, indicating that part of
the variability within hearts can be ascribed to imprecision
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Fig. 2 Intra-heart variability in protein phosphorylation. a–c cMyBP-C phosphorylation. d–f cTnI phosphorylation. The coefﬁcient of variation
is indicated above the bars for each heart
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123of the technique. Since the samples weighted approxi-
mately 2 g, our results do not rule out the possibility
of transmural differences in protein phosphorylation
(Cazorla et al. 2005; Davis et al. 2001).
Figure 2 demonstrates inter-patient variability in protein
phosphorylation. Furthermore, it can be appreciated that in
general the phosphorylation of cMyBP-C and cTnI is lower
in HCM and DCM compared to donor, in accordance
with previous data obtained in ischemic heart disease
(van der Velden et al. 2003).
In conclusion, we demonstrate comparable variability of
cMyBP-C and cTnI phosphorylation within hearts from
HCM and DCM patients and donors, indicating that, within
the precision of our measurements, small left ventricular
tissue samples of end stage-failing hearts from primary
cardiomyopathy patients are representative for the region
they were taken from.
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Fig. 3 The coefﬁcient of variation, a measure of how much the
individual values of each heart differed from the mean, was on
average not signiﬁcantly different between donor, HCM and DCM for
the phosphorylation status of cMyBP-C (a) or cTnI (b) (closed
symbols). Within the analysis of cMyBP-C phosphorylation, exclu-
sion of outliers (HCM 1 and DCM 3) lowered the mean coefﬁcient of
variation and the SEM in HCM, while the average coefﬁcient of
variation of the DCM group was slightly increased (as indicated by
the arrow, open symbols). After exclusion of the outliers there was
still no signiﬁcant difference in coefﬁcient of variation among the
groups. Groups were compared by one-way ANOVA, P\0.05 was
considered signiﬁcant
302 J Muscle Res Cell Motil (2009) 30:299–302
123